Dengue Fever Treatment Market Snapshot (2023 to 2033)
The global Dengue Fever Treatment Market is expected to garner a market value of US$ 877.82 Million in 2023 and is expected to accumulate a market value of US$ 5435.25 Million by registering a CAGR of 20% in the forecast period 2023 to 2033. The market for Dengue Fever Treatment registered a CAGR of 11% in the historical period 2018 to 2022.
Studies state that in 2022, and as of 19 December, 3,766,153 cases and 3582 deaths have been reported. The majority of cases have been reported from Brazil (2,182,229), Vietnam (325 604), Philippines (201,509), India (110,473), and Indonesia (94,355).
Report Attribute
Details
Expected Market Value (2023)
US$ 877.82 Million
Anticipated Forecast Value (2033)
US$ 5435.25 Million
Projected Growth Rate (2023 to 2033)
20% CAGR
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Dengue Fever Treatment Market Demand Analysis vs. Forecast 2023 to 2033
According to market research and competitive intelligence provider Future Market Insights- the market for Dengue Fever Treatment reflected a value of 11% during the historical period, 2018 to 2022.
A series of international-level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering dengue fever treatments. Majority growth is likely to remain concentrated across the Asia-Pacific region, attributed to maximum dengue fever concentration as well as the presence of reputed regional pharmaceutical giants.
In its new study, ESOMAR-certified market research and consulting firm Future Market Insights (FMI) offers insights into key factors driving demand for dengue fever treatment. In the years to come, increasing focus by government organizations and private agencies like WHO and pharmaceutical companies to create awareness of dengue is fuelling market growth. Thus, the market for Dengue Fever Treatment is expected to register a CAGR of 20% in the forecast period 2023 to 2033.
Which are Some Prominent Drivers of the Dengue Fever Treatment Market?
Increased incidence of Dengue Cases to Push the Market Growth
According to the World Health Organization, the incidence of dengue has grown dramatically over recent decades. A vast majority of the cases are asymptomatic, mild, or self-managed, and hence the actual number of infections is highly under-reported. One modeling estimate indicates 390 Million dengue virus infections per year (95% credible interval 284-528 Million), of which 96 Million manifest clinically.
Another clinical study has established that nearly 4 billion people are at risk of infection. Despite a risk of infection existing in 129 countries, 70% of the actual burden is concentrated in Asia. Furthermore, the number of reported dengue cases over the past two decades has increased eightfold since the past 20 years, from 505,430 cases in 2000 to over 2.4 Million in 2019, with death rates climbing from 960 to 4032.
As of 2020, dengue continues to affect several countries, with the Americas reporting over 3 Million cases out of which 25,000 are classified as severe. High incidences were also reported across Bangladesh (101,000), Malaysia (131,000), the Philippines (420,000), and Vietnam (320,000). Hence, major pharmaceutical giants are accelerating the pace of their ongoing clinical trials, as well as initiating new ones so as to capitalize on this opportunity and expand their presence.
Find your sweet spots for generating winning opportunities in this market.
What are the Challenges Faced by the Dengue Fever Treatment Market?
Expensive Cost of Treatment to restrict Market Growth
The expensive treatment of Dengue Fever Treatment, less awareness of Dengue Fever Treatment disease, and insubstantial treatment options are hampering the market growth. Furthermore, lack of health remuneration policies, rise in cost, and side effects associated with certain treatments are expected to hinder the market growth.
Region-Wise Insights
How is the Market for Dengue Fever Treatment Market Turning Out in the Asia Pacific Region?
Improvement in healthcare spending propelling the growth of Dengue Fever Treatment in Asia Pacific
The Asia Pacific is expected to exhibit a significant growth rate of all regions over the forecast period, with a CAGR of 5% during the forecast period. The growth is owed to increased awareness, significant increases in healthcare spending, and a rising frequency of the Dengue Fever Treatment Market in the region. Asia Pacific is an emerging market due to the increase in point care approach to health & care. An increasing number of hospitals in India and China makes a promising market for the market worldwide.
India-based Serum Institute initiated a clinical trial in 2017 for verifying the efficacy of its VIS513 monoclonal antibody to treat dengue infections throughout the Indian subcontinent. The company holds exclusive licenses to the treatment for commercialization across all seven countries and has invested a sum of US$ 5 million, which would yield an additional US$ 34 million upon achievement of the set milestone.
Similarly, Sun Pharmaceutical Industries Ltd. has forged a partnership with the International Center for Genetic Engineering and Biotechnology (ICGEB) to develop a dengue vaccine that is safe, effective, and affordable. As per this agreement, Sun Pharma is funding and developing the DSV-4 vaccine candidate that targets all four serotypes of the dengue virus.
What are the Factors Boosting the Market for Dengue Fever Treatment in North America?
Technological Advancements Shaping Landscape for Dengue Fever Treatment in North America
North America is anticipated to acquire a market share of about 25% in the forecast period. This growth is attributable to the rising prevalence of the condition in the region.
According to the Centers for Disease Control and Prevention (CDC), dengue outbreaks occasionally occur in the continental U.S.A. However, these outbreaks are common across its overseas territories, including Puerto Rico, the US Virgin Islands, and American Samoa respectively. On the mainland, outbreaks were frequent across Hawaii (2015), Florida (2013, 2020), and Texas (2013).
Between January 2010 and December 2017, a total of 5,387 dengue cases were reported. The majority of these were associated with travel (5,009; 93%), with the median patient age at 41 years. Over half of the cases (54%) were reported from five states: New York (18%), California (16%), Florida (14%), Texas (5%), and New Jersey (5%). This led to an overall hospitalization rate of 40%.
In May 2019, the US Food & Drug Administration approved the use of Sanofi’s Dengvaxia® live attenuated vaccine which is administered as three separate injections in 9-through-16-year-olds. In addition, existing trials for the ChimeriVaxTM Tetravalent Dengue Vaccine are expected to yield conclusive results in the future, paving the way for the entry of another potential vaccine candidate. Furthermore, due to the presence of leading technological advancements in the healthcare sector and healthcare facilities with the advancements in technology, efficient treatments are being introduced.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-Wise Insights
By Type, Which Segment is Likely to Account for a Prominent Share?
Vaccines as an effective treatment to drive the market
Dengue vaccine development has entered an important stage of its life cycle - with a host of pharmaceutical giants expected to present the results of their extensive clinical trials initiated in the past decade or half a decade. Considering these factors, vaccines are considered an effective treatment to account
Presently, Dengvaxia is being marketed by pharmaceutical giant Sanofi Pasteur and has been approved across 19 countries and the European Union. It also gained approval across the USA market in 2019. The vaccine is approximately 76% effective in preventing symptomatic, laboratory-confirmed dengue diseases in 9 through 16 years of age. Simultaneously, several other corporations are developing new vaccine candidates, thus generating immense revenue potential.
By End-user, Which Segment is Likely to Account for a Significant Share?
Hospitals to take the lead and drive market growth
According to the FMI analysis, Hospitals account for the largest market share. The requirement for several hospital stays and visits during the dengue fever treatment facilitates the growth of this segment. Hospitals are also emphasizing the delivery of various comprehensive programs with personalized and professional support in the management of target diseases.
Start-up Scenario
Key start-up players in the Dengue Fever Treatment Market are-
The US-based startup mFluiDx offers a DNA-based diagnostic test. It combines nucleic acid diagnostics with vacuum-based microfluidics technology to enable multi-target testing. As a result of their technology, the diagnostic test offers a low-cost alternative to conventional PCR testing. It is also a highly sensitive and automated point-of-care diagnostic assay for the detection of infectious diseases.
Singaporean startup StratifiCare provides a severe dengue prediction kit. It uses a set of proprietary biomarkers and a common laboratory assay platform. The solution is currently in the clinical development stage. The kit is able to deliver accuracy with 90% sensitivity and 97% specificity, in turn, reducing hospitalization costs.
Market Competition
Key players in the Dengue Fever Treatment Market are Mylan N.V, Pfizer Inc., Teva Pharmaceuticals USA, Inc., Perrigo Company plc, GlaxoSmithKline plc, Dr. Reddy’s Laboratories Limited, Fresenius Kabi USA, Sun Pharmaceutical Industries Ltd., ABIVAX, Aurobindo Pharma, Baxter, EMERGEX VACCINES, Hikma Pharmaceuticals PLC, Sanofi, and Takeda Pharmaceutical Company Limited among other global players.
In March 2021, Takeda Pharmaceutical Company Limited announced the approval of its TAK-003 dengue vaccine candidate by the European Medicines Agency (EMA), currently under investigation for preventing any outbreaks in individuals aged 4 to 60. The company also intends to apply for regulatory approvals in Argentina, Brazil, Columbia, Indonesia, Malaysia, Mexico, Singapore, Sri Lanka, and Thailand through 2021.
In December 2021, Kao Corporation announced the launch of a campaign to reduce the spread of dengue fever. Kao used its original technology to develop similar products as part of the initiative. Kao distributed 80,000 units of the product in partnership with the Thai Ministry of Public Health and donated 6.5 Million Thai baht to the Ministry in total, which includes the items. In addition, the initiative enhanced the demonstration and research efforts as well as raised overall awareness of Dengue disease.
Report Scope
Report Attribute
Details
Market Value in 2023
US$ 877.82 Million
Market Value in 2033
US$ 5435.25 Million
Growth Rate
CAGR of 20% from 2023 to 2033
Base Year for Estimation
2022
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in USD Million and CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
Type
End-User
Route of Administration
Region
Regions Covered
North America
Latin America
Europe
Asia Pacific
Middle East & Africa (MEA)
Key Countries Profiled
The USA
Canada
Brazil
Argentina
Germany
The United Kingdom
France
Spain
Italy
Nordics
BENELUX
Australia & New Zealand
China
India
Association of Southeast Asian Nations
Gulf Cooperation Council
South Africa
Key Companies Profiled
Mylan N.V, Pfizer Inc., Teva Pharmaceuticals USA, Inc., Perrigo Company plc, GlaxoSmithKline plc, Dr. Reddy’s Laboratories Limited, Fresenius Kabi USA, Sun Pharmaceutical Industries Ltd., ABIVAX, Aurobindo Pharma, Baxter, EMERGEX VACCINES, Hikma Pharmaceuticals PLC, Sanofi, and Takeda Pharmaceutical Company Limited
Customization
Available Upon Request
Key Segments Profiled in the Dengue Fever Treatment Industry Survey
Type:
Drug
Vaccines
Route of Administration:
Oral
Parenteral
End-User:
Hospital
Homecare
Specialty Clinics
Others
Region:
North America
Latin America
Europe
Asia Pacific
Middle East & Africa
Frequently Asked Questions
How Big is the Dengue Fever Treatment Market?
Worldwide market is predicted to earn almost US$ 877.82 million in 2023.
How Much Growth is Expected in Global Dengue Fever Treatment Market?
The global market could witness increment with 20% CAGR through 2033.
What is the Projected Market Value of the Global Dengue Fever Treatment Market?
The overall market is projected to reach almost US$ 5,435.25 million by 2033
Which Region has a Massive Share in the Global Dengue Fever Treatment Market?
Total adoption in North America could be around 25% of the global demand by 2033.
Which Segment of Dengue Fever Treatment Market has the Higher Growth Potential?
Vaccines segment accounts a sizeable portion of the overall market.
Table of Content
1. Executive Summary | Dengue Fever Treatment Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Type, 2023 to 2033
5.3.1. Drug
5.3.2. Vaccines
5.4. Y-o-Y Growth Trend Analysis By Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Type, 2023 to 2033
6. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
6.3.1. Oral
6.3.2. Parenteral
6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033
7. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-user
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End-user, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-user, 2023 to 2033
7.3.1. Hospitals
7.3.2. Homecare
7.3.3. Specialty Clinics
7.3.4. Others
7.4. Y-o-Y Growth Trend Analysis By End-user, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By End-user, 2023 to 2033
8. Global Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. MEA
8.4. Market Attractiveness Analysis By Region
9. North America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. USA
9.2.1.2. Canada
9.2.2. By Type
9.2.3. By Route of Administration
9.2.4. By End-user
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Type
9.3.3. By Route of Administration
9.3.4. By End-user
9.4. Key Takeaways
10. Latin America Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Type
10.2.3. By Route of Administration
10.2.4. By End-user
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Type
10.3.3. By Route of Administration
10.3.4. By End-user
10.4. Key Takeaways
11. Europe Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. UK
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Rest of Europe
11.2.2. By Type
11.2.3. By Route of Administration
11.2.4. By End-user
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Type
11.3.3. By Route of Administration
11.3.4. By End-user
11.4. Key Takeaways
12. Asia Pacific Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. South Korea
12.2.1.4. Singapore
12.2.1.5. Thailand
12.2.1.6. Indonesia
12.2.1.7. Australia
12.2.1.8. New Zealand
12.2.1.9. Rest of Asia Pacific
12.2.2. By Type
12.2.3. By Route of Administration
12.2.4. By End-user
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Type
12.3.3. By Route of Administration
12.3.4. By End-user
12.4. Key Takeaways
13. MEA Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. GCC Countries
13.2.1.2. South Africa
13.2.1.3. Israel
13.2.1.4. Rest of MEA
13.2.2. By Type
13.2.3. By Route of Administration
13.2.4. By End-user
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Type
13.3.3. By Route of Administration
13.3.4. By End-user
13.4. Key Takeaways
14. Key Countries Analysis
14.1. USA
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2022
14.1.2.1. By Type
14.1.2.2. By Route of Administration
14.1.2.3. By End-user
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2022
14.2.2.1. By Type
14.2.2.2. By Route of Administration
14.2.2.3. By End-user
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2022
14.3.2.1. By Type
14.3.2.2. By Route of Administration
14.3.2.3. By End-user
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2022
14.4.2.1. By Type
14.4.2.2. By Route of Administration
14.4.2.3. By End-user
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2022
14.5.2.1. By Type
14.5.2.2. By Route of Administration
14.5.2.3. By End-user
14.6. UK
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2022
14.6.2.1. By Type
14.6.2.2. By Route of Administration
14.6.2.3. By End-user
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2022
14.7.2.1. By Type
14.7.2.2. By Route of Administration
14.7.2.3. By End-user
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2022
14.8.2.1. By Type
14.8.2.2. By Route of Administration
14.8.2.3. By End-user
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2022
14.9.2.1. By Type
14.9.2.2. By Route of Administration
14.9.2.3. By End-user
14.10. China
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2022
14.10.2.1. By Type
14.10.2.2. By Route of Administration
14.10.2.3. By End-user
14.11. Japan
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2022
14.11.2.1. By Type
14.11.2.2. By Route of Administration
14.11.2.3. By End-user
14.12. South Korea
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2022
14.12.2.1. By Type
14.12.2.2. By Route of Administration
14.12.2.3. By End-user
14.13. Singapore
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2022
14.13.2.1. By Type
14.13.2.2. By Route of Administration
14.13.2.3. By End-user
14.14. Thailand
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2022
14.14.2.1. By Type
14.14.2.2. By Route of Administration
14.14.2.3. By End-user
14.15. Indonesia
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2022
14.15.2.1. By Type
14.15.2.2. By Route of Administration
14.15.2.3. By End-user
14.16. Australia
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2022
14.16.2.1. By Type
14.16.2.2. By Route of Administration
14.16.2.3. By End-user
14.17. New Zealand
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2022
14.17.2.1. By Type
14.17.2.2. By Route of Administration
14.17.2.3. By End-user
14.18. GCC Countries
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2022
14.18.2.1. By Type
14.18.2.2. By Route of Administration
14.18.2.3. By End-user
14.19. South Africa
14.19.1. Pricing Analysis
14.19.2. Market Share Analysis, 2022
14.19.2.1. By Type
14.19.2.2. By Route of Administration
14.19.2.3. By End-user
14.20. Israel
14.20.1. Pricing Analysis
14.20.2. Market Share Analysis, 2022
14.20.2.1. By Type
14.20.2.2. By Route of Administration
14.20.2.3. By End-user
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Type
15.3.3. By Route of Administration
15.3.4. By End-user
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. GeneOne Life Science, Inc
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. Johnson & Johnson
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. Merck Sharp & Dohme Corp.
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. Novartis AG
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. Sanofi
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. Serum Institute of India Pvt. Ltd
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. Sun Pharmaceutical Industries Ltd.
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. Takeda Pharmaceutical Company Limited
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. Pfizer Inc.
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
16.1.10. Teva Pharmaceuticals
16.1.10.1. Overview
16.1.10.2. Product Portfolio
16.1.10.3. Profitability by Market Segments
16.1.10.4. Sales Footprint
16.1.10.5. Strategy Overview
16.1.10.5.1. Marketing Strategy
17. Assumptions & Acronyms Used18. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Value (US$ Million) Forecast by Type, 2018 to 2033
Table 3: Global Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 4: Global Value (US$ Million) Forecast by End-user, 2018 to 2033
Table 5: North America Value (US$ Million) Forecast by Country, 2018 to 2033
Table 6: North America Value (US$ Million) Forecast by Type, 2018 to 2033
Table 7: North America Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 8: North America Value (US$ Million) Forecast by End-user, 2018 to 2033
Table 9: Latin America Value (US$ Million) Forecast by Country, 2018 to 2033
Table 10: Latin America Value (US$ Million) Forecast by Type, 2018 to 2033
Table 11: Latin America Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 12: Latin America Value (US$ Million) Forecast by End-user, 2018 to 2033
Table 13: Europe Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Europe Value (US$ Million) Forecast by Type, 2018 to 2033
Table 15: Europe Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 16: Europe Value (US$ Million) Forecast by End-user, 2018 to 2033
Table 17: Asia Pacific Value (US$ Million) Forecast by Country, 2018 to 2033
Table 18: Asia Pacific Value (US$ Million) Forecast by Type, 2018 to 2033
Table 19: Asia Pacific Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 20: Asia Pacific Value (US$ Million) Forecast by End-user, 2018 to 2033
Table 21: MEA Value (US$ Million) Forecast by Country, 2018 to 2033
Table 22: MEA Value (US$ Million) Forecast by Type, 2018 to 2033
Table 23: MEA Value (US$ Million) Forecast by Route of Administration, 2018 to 2033
Table 24: MEA Value (US$ Million) Forecast by End-user, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Value (US$ Million) by Type, 2023 to 2033
Figure 2: Global Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 3: Global Value (US$ Million) by End-user, 2023 to 2033
Figure 4: Global Value (US$ Million) by Region, 2023 to 2033
Figure 5: Global Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 6: Global Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 7: Global Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 8: Global Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 9: Global Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 10: Global Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 11: Global Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 12: Global Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 13: Global Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 14: Global Value (US$ Million) Analysis by End-user, 2018 to 2033
Figure 15: Global Value Share (%) and BPS Analysis by End-user, 2023 to 2033
Figure 16: Global Y-o-Y Growth (%) Projections by End-user, 2023 to 2033
Figure 17: Global Attractiveness by Type, 2023 to 2033
Figure 18: Global Attractiveness by Route of Administration, 2023 to 2033
Figure 19: Global Attractiveness by End-user, 2023 to 2033
Figure 20: Global Attractiveness by Region, 2023 to 2033
Figure 21: North America Value (US$ Million) by Type, 2023 to 2033
Figure 22: North America Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 23: North America Value (US$ Million) by End-user, 2023 to 2033
Figure 24: North America Value (US$ Million) by Country, 2023 to 2033
Figure 25: North America Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 26: North America Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 27: North America Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 28: North America Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 29: North America Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 30: North America Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 31: North America Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 32: North America Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 33: North America Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 34: North America Value (US$ Million) Analysis by End-user, 2018 to 2033
Figure 35: North America Value Share (%) and BPS Analysis by End-user, 2023 to 2033
Figure 36: North America Y-o-Y Growth (%) Projections by End-user, 2023 to 2033
Figure 37: North America Attractiveness by Type, 2023 to 2033
Figure 38: North America Attractiveness by Route of Administration, 2023 to 2033
Figure 39: North America Attractiveness by End-user, 2023 to 2033
Figure 40: North America Attractiveness by Country, 2023 to 2033
Figure 41: Latin America Value (US$ Million) by Type, 2023 to 2033
Figure 42: Latin America Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 43: Latin America Value (US$ Million) by End-user, 2023 to 2033
Figure 44: Latin America Value (US$ Million) by Country, 2023 to 2033
Figure 45: Latin America Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 46: Latin America Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 47: Latin America Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 48: Latin America Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 49: Latin America Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 50: Latin America Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 51: Latin America Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 52: Latin America Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 53: Latin America Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 54: Latin America Value (US$ Million) Analysis by End-user, 2018 to 2033
Figure 55: Latin America Value Share (%) and BPS Analysis by End-user, 2023 to 2033
Figure 56: Latin America Y-o-Y Growth (%) Projections by End-user, 2023 to 2033
Figure 57: Latin America Attractiveness by Type, 2023 to 2033
Figure 58: Latin America Attractiveness by Route of Administration, 2023 to 2033
Figure 59: Latin America Attractiveness by End-user, 2023 to 2033
Figure 60: Latin America Attractiveness by Country, 2023 to 2033
Figure 61: Europe Value (US$ Million) by Type, 2023 to 2033
Figure 62: Europe Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 63: Europe Value (US$ Million) by End-user, 2023 to 2033
Figure 64: Europe Value (US$ Million) by Country, 2023 to 2033
Figure 65: Europe Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 66: Europe Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 67: Europe Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 68: Europe Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 69: Europe Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 70: Europe Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 71: Europe Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 72: Europe Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 73: Europe Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 74: Europe Value (US$ Million) Analysis by End-user, 2018 to 2033
Figure 75: Europe Value Share (%) and BPS Analysis by End-user, 2023 to 2033
Figure 76: Europe Y-o-Y Growth (%) Projections by End-user, 2023 to 2033
Figure 77: Europe Attractiveness by Type, 2023 to 2033
Figure 78: Europe Attractiveness by Route of Administration, 2023 to 2033
Figure 79: Europe Attractiveness by End-user, 2023 to 2033
Figure 80: Europe Attractiveness by Country, 2023 to 2033
Figure 81: Asia Pacific Value (US$ Million) by Type, 2023 to 2033
Figure 82: Asia Pacific Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 83: Asia Pacific Value (US$ Million) by End-user, 2023 to 2033
Figure 84: Asia Pacific Value (US$ Million) by Country, 2023 to 2033
Figure 85: Asia Pacific Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 86: Asia Pacific Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 87: Asia Pacific Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 88: Asia Pacific Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 89: Asia Pacific Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 90: Asia Pacific Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 91: Asia Pacific Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 92: Asia Pacific Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 93: Asia Pacific Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 94: Asia Pacific Value (US$ Million) Analysis by End-user, 2018 to 2033
Figure 95: Asia Pacific Value Share (%) and BPS Analysis by End-user, 2023 to 2033
Figure 96: Asia Pacific Y-o-Y Growth (%) Projections by End-user, 2023 to 2033
Figure 97: Asia Pacific Attractiveness by Type, 2023 to 2033
Figure 98: Asia Pacific Attractiveness by Route of Administration, 2023 to 2033
Figure 99: Asia Pacific Attractiveness by End-user, 2023 to 2033
Figure 100: Asia Pacific Attractiveness by Country, 2023 to 2033
Figure 101: MEA Value (US$ Million) by Type, 2023 to 2033
Figure 102: MEA Value (US$ Million) by Route of Administration, 2023 to 2033
Figure 103: MEA Value (US$ Million) by End-user, 2023 to 2033
Figure 104: MEA Value (US$ Million) by Country, 2023 to 2033
Figure 105: MEA Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 106: MEA Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 107: MEA Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 108: MEA Value (US$ Million) Analysis by Type, 2018 to 2033
Figure 109: MEA Value Share (%) and BPS Analysis by Type, 2023 to 2033
Figure 110: MEA Y-o-Y Growth (%) Projections by Type, 2023 to 2033
Figure 111: MEA Value (US$ Million) Analysis by Route of Administration, 2018 to 2033
Figure 112: MEA Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033
Figure 113: MEA Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033
Figure 114: MEA Value (US$ Million) Analysis by End-user, 2018 to 2033
Figure 115: MEA Value Share (%) and BPS Analysis by End-user, 2023 to 2033
Figure 116: MEA Y-o-Y Growth (%) Projections by End-user, 2023 to 2033
Figure 117: MEA Attractiveness by Type, 2023 to 2033
Figure 118: MEA Attractiveness by Route of Administration, 2023 to 2033
Figure 119: MEA Attractiveness by End-user, 2023 to 2033
Figure 120: MEA Attractiveness by Country, 2023 to 2033
